Compare Charles River Laboratories Intl. Inc (CRL) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Prologis Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $286.53 (market cap $13.46B), while Prologis Inc trades at $140.48 (market cap $132.57B). The key difference: Prologis Inc is far larger — about 9.8× Charles River Laboratories Intl. Inc's market cap, and Prologis Inc pays a 3.07% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | PLD | |
|---|---|---|
Market Cap | $13.46B | $132.57B |
Sector | Health | Real Estate |
52-Week High | $282.00 | $149.96 |
52-Week Low | $145.57 | $104.81 |
Enterprise Value | $16.30B | $167.31B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Prologis (PLD) trades at $139.75, up 0.74% today, with strong recent earnings beats but a bearish technical signal. The company announced a major $18.8 billion acquisition of SEGRO, expanding its European footprint, while financials show robust profitability with a 45.79% net income margin. Cash flow trends are mixed, with 2025 showing a net outflow but a projected recovery in 2026.
The outlook is positive due to strategic growth via acquisition and consistent earnings outperformance, though risks include integration challenges from the SEGRO deal and a high P/E ratio of 31.07. Analyst consensus is bullish with a $159.22 price target, suggesting significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
